Trial Profile
Phase I/II trial of YHI-1003 plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jun 2016
Price :
$35
*
At a glance
- Drugs Perifosine (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Yakult Honsha
- 04 Jan 2012 New trial record